PROFILE

한용만 교수

Therapeutic effects of Fasudil on various symptoms of Fabry disease

I will introduce a putative cellular modeling for Fabry disease (FD) using vascular endothelial cells derived from FD-induced pluripotent stem cells and development of a potent drug for Fabry disease therapy in vitro and in vivo.

KAIST 의과학대학원

EDUCATION

1977.03-1984. 02 BS, Department of Animal Sciences, Konkuk University, Korea
1984.03-1986.02 MS, Department of Animal Sciences, Konkuk University, Korea
1988.03-1993.08 PhD., Department of Biological Sciences, KAIST, Korea

PROFESSIONAL EXPERIENCE

1986.03-2006.05 Principal Research Scientist, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
1997.03-1998.08 Postdoc Fellow, Univ. of Missouri-Columbia, USA
1999.03-2003.02 Adjunct Professor, Chungnam National University
2004.01-2007.12 Editorial Board Member, Developmental Dynamics
2009.12-2012.12 Adjunct Professor, Hanam Agricultural University, China
2011.09-2012.08 Head, Department of Biological Sciences, KAIST
2012.08-2013.04 Director, Academic Affairs, KAIST
2014.01-2016.05 Editor-in-chief, International Journal of Stem Cells
2016.01-2016.12 President, Korean Society for Stem Cell Research (KSSCR)
2016.08-2017.06 Head, Graduate School of Medical Science and Engineering, KAIST
2015.07-2019.06 Editorial Board Member, Journal of Biological Chemistry
2016.12-2020.06 Director, BioMedical Research Center, KAIST
2017.03-2021.02 Dean, College of Life Science & Bioengineering, KAIST
2006.06-2022.12 Professor, Department of Biological Sciences, KAIST
2022.12-2023.02 Professor, Graduate School of Medical Science & Engineering, KAIST
2011.11-present Fellow, The Korean Academy of Science and Technology (KAST)
2021.07-present. Chairman of the Board of Directors, Korean Fund for Regenerative Medicine
2022.12-present. Member of Board of Directors, National Research Foundation of Korea
2025.03-present. Member of Board of Directors, KAST
2023.03-present. Emeritus Professor, Graduate School of Medical Science & Engineering, KAIST

PUBLICATIONS

1. Choi JB, Seol DW, Do HS, Yang HY, Kim TM, Byun Y, Park JM, Choi J, Chung WS, Suh JM, Lee BH, Wee G, Han YM (2025) Therapeutic effects of lomerizine on vasculopathy in Fabry disease. Scientific Reports 15, 11355.
2. Son G, Na Y, Kim Y, Son JH, Clemenson GD, Schafer S, Yoo JY, Parylak SL, Paquoia A, Do H, Ahn I, Ju M, Kang C, Ju Y, Park Y, Kim G, Paik SB, Hur J, Han YM, Lee SH, Gage FH, Kim JS, Han J. (2024) miR-124 coordinates metabolic regulators acting at early stages of human neurogenesis. Communications Biology 7, 1393.
3. Choi JB, Seol DW, Do HS, Yang HY, Kim TM, Byun Y, Park JM, Choi J, Chung WS, Suh JM, Lee BH, Wee G, Han YM. (2023) Lomerizine treatment improves vasculopathological phenotypes in Fabry disease models. Submitted.
4. Byun Y.G, Kim NS, Kim G, Jeon YS, Choi JB, Park CW, Kim K, Jang H, Kim J, Kim E, Han YM, Yoon KJ, Lee SH, Chung WS. (2023) Stress induces behavioral anomalities by increasing expression of phagocytic receptor MERTK in astrocytes to promote synapse phagocytosis. Immunity 56 (9), 2105-2120.
5. Cho G, Hyun K, Choi J, Shin EJ, Kim B, Kim J, Kim H, Han YM. (2023) Arginine 65 methylation of Neurogenin 3 by PRMT1 is a prerequisite for normal development of hESCs into pancreatic endocrine cells. Experimental & Molecular Medicine 55, 1506-1519.